Abstract:BACKGROUND:Randomized controlled trials are considered the gold standard for evaluating experimental treatments but often require large sample sizes. Single-arm trials require smaller sample sizes but are subject to bias when using historical control data for comparative inferences. This article presents a Bayesian adaptive synthetic-control design that exploits historical control data to create a hybrid of a single-arm trial and a randomized controlled trial.METHODS:The Bayesian adaptive synthetic control design has two stages. In stage 1, a prespecified number of patients are enrolled in a single arm given the experimental treatment. Based on the stage 1 data, applying propensity score matching and Bayesian posterior prediction methods, the usefulness of the historical control data for identifying a pseudo sample of matched synthetic-control patients for making comparative inferences is evaluated. If a sufficient number of synthetic controls can be identified, the single-arm trial is continued. If not, the trial is switched to a randomized controlled trial. The performance of The Bayesian adaptive synthetic control design is evaluated by computer simulation.RESULTS:The Bayesian adaptive synthetic control design achieves power and unbiasedness similar to a randomized controlled trial but on average requires a much smaller sample size, provided that the historical control data patients are sufficiently comparable to the trial patients so that a good number of matched controls can be identified in the historical control data. Compared to a single-arm trial, The Bayesian adaptive synthetic control design yields much higher power and much smaller bias.CONCLUSION:The Bayesian adaptive synthetic-control design provides a useful tool for exploiting historical control data to improve the efficiency of single-arm phase II clinical trials, while addressing the problem of bias when comparing trial results to historical control data. The proposed design achieves power similar to a randomized controlled trial but may require a substantially smaller sample size.

Statistical Considerations in Design of Clinical Trial for Fixed Dose Drug Combination

A Bayesian Dose Finding Design for Oncology Clinical Trials of Combinational Biological Agents

Bayesian Dose Finding for Combined Drugs with Discrete and Continuous Doses

Phase I Trial Design for Drug Combinations with Bayesian Model Averaging.

Statistical and practical considerations in planning and conduct of dose-optimization trials

The Ci3+3 Design for Dual-Agent Combination Dose-Finding Clinical Trials

Dynamic Ordering Design for Dose Finding in Drug‐combination Trials

Rationale and strategies for formulation development of oral fixed dose combination drug products

An Adaptive Trial Design to Optimize Dose-Schedule Regimes with Delayed Outcomes

Designing Dose-Optimization Studies in Cancer Drug Development: Discussions with Regulators

Development of a Robust Control Strategy for Fixed-Dose Combination Bilayer Tablets with Integrated Quality by Design, Statistical, and Process Analytical Technology Approach

A Nonparametric Bayesian Design for Drug Combination Cancer Trials

A Dose-Finding Design for Phase I Clinical Trials Based on Bayesian Stochastic Approximation

Adaptive designs for identifying optimal biological dose for molecularly targeted agents.

BASIC: A Bayesian Adaptive Synthetic-Control Design for Phase II Clinical Trials.

Time-to-event Model-Assisted Designs for Dose-Finding Trials with Delayed Toxicity

A new function for drug combination dose finding trials

DOD-Combo: Bayesian dose finding design in combination trials with meta-analytic-predictive prior

A Comparative Study of Adaptive Trial Designs for Dose Optimization.

SDF-Bayes: Cautious Optimism in Safe Dose-Finding Clinical Trials with Drug Combinations and Heterogeneous Patient Groups

Two-dimensional calibration-free odds design for phase I drug-combination trials